Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access
- DOI
- 10.2147/ceor.s567932
- Published
- 2025-12
- Container
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2147/ceor.s567932,
title = {Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access},
author = {Nigel Rawson},
year = {2025},
journal = {ClinicoEconomics and Outcomes Research},
doi = {10.2147/ceor.s567932},
url = {https://doi.org/10.2147/ceor.s567932}
}RIS
TY - JOUR TI - Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access AU - Nigel Rawson PY - 2025 JO - ClinicoEconomics and Outcomes Research DO - 10.2147/ceor.s567932 UR - https://doi.org/10.2147/ceor.s567932 ER -
APA
Rawson, N. (2025). Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s567932
Source records
- crossref · retrieved 2026-09-27T01:15:59.957Z